QSI Q2 2026 - Post-Call Earnings Update
Verdict
- Nothing material changed in the numbers. Full-year 2026 guidance of approximately $1m revenue, adjusted operating expenses of $98m or less and total cash usage of $93m or less was reiterated verbatim.
- The Proteus delay is internal, not customer-driven. Management was explicit that no new customer requirement caused it: testing of integrated units showed some machines performing below internal specification, so an extra design cycle was added to fix repeatability and manufacturability before production.
- The launch specification improved. Proteus is now expected to launch with 19 or 20 amino acids rather than the 18 previously planned, with all 20 still to be demonstrated in 2026.
- The one thing that matters: the 20% reduction in force is worth roughly $12m annualised, but the CFO said R&D will run "fairly consistent to prior quarters." The savings therefore come from everywhere except the program — commercial, G&A and support — which is the organisation that has to launch and sell Proteus in Q2 2027 and now enters that launch smaller.
- Tone flag: management repeatedly called the decision "more responsible and capital efficient", while confirming the early access program has slipped with no replacement date.
Consensus scorecard
| Metric / basis | Quartr actual | API Ninjas consensus | Beat/Miss | Beat/Miss % |
|---|---|---|---|---|
| Revenue (total revenue) | $0.344m | $0.302m | Beat +$0.042m | +13.9% |
| EPS (GAAP basic and diluted) | $(0.11) | $(0.1133) | Beat +$0.0033 | +2.9% |
Guidance & KPIs
| Item | New on the call | Prior guide | Prior-year actual |
|---|---|---|---|
| Proteus commercial launch | Q2 2027 | End of 2026 | — |
| Amino acids at launch | 19 or 20 | 18, with 20 in 2027 | — |
| Reduction in force savings | ~$12m annualised once complete | Not previously quantified | — |
| Cash runway | Into Q4 2028 | Into Q2 2028 | — |
| Early access program | Deferred, no date given | Following launch prep | Not started |
| Qualified institutions interested in Proteus | More than 250 | Not previously given | — |
Management commentary
- On the cause: "It wasn't driven by some sort of new feedback from customers." The trigger was internal assessment of repeatability across integrated units and of first-pass manufacturing yield.
- The additional cycle is hardware-only; reagent and consumable development "have really been tracking largely to our expectation."
- Semiconductor exposure falls with Proteus — the consumable moves from a CMOS chip to a fused silica array, leaving only a GPU in the instrument, which management says it can stockpile.
- New commercial framing: a claimed $4bn-plus annual non-human proteomics opportunity in pathogen and agricultural research, described as conservative and excluding environmental, animal health, industrial and food applications.
- Not addressed: what Q2 2027 slippage would cost, and what the reduction in force does to commercial readiness at launch.
Quality of earnings
- The expense decline is a prior-year comparison, not cost control. GAAP operating expenses fell 15% to $25.8m from $30.5m, but the 2025 quarter carried $3.362m of legal settlement expense; adjusted operating expenses fell only 5%, to $22.6m from $23.8m.
- Profitability improved while the business shrank. Adjusted EBITDA improved 5% to $(21.2)m against a 42% revenue decline to $344k; gross profit of $172k funded none of a roughly $21m quarterly burn.
- The per-share loss flatters the result. Net loss narrowed 18% to $23.5m from $28.8m while loss per share narrowed 31% to $(0.11), because the share count rose 19% to 217.8m.
Gotchas & watch items
- The reiterated $98m adjusted opex and $93m cash-usage guides still exclude the ~$12m of annualised reduction-in-force savings, which land after 2026.
- The runway extension to Q4 2028 is bought with headcount, not revenue: full-year revenue guidance of ~$1m against $602k in the first half implies the top line keeps falling.
- Early access has not started and now has no date, so the first external validation of Proteus hardware moves out with it.
- Management would not commit beyond "we think we've factored that in" on the Q2 2027 date, having just missed the prior one.
Event: https://web.quartr.com/companies/5270/events/662686/overview Retrieved: 2026-08-13T21:47:00Z Comparison mode: maximal · Scorecard contract: v1